SER 10-Q: SEC filing
Serina Therapeutics
Filed with the SEC on · accession 0001708599-26-000068
SER filed a 10-Q (quarterly report) with the SEC on Nov 12, 2026. The quarterly report: unaudited results for the quarter plus management’s comments. The stock moved -6.0% by the first close after the filing.
Summary of the filing
Serina Therapeutics filed its Q3 2026 Form 10-Q, reporting financial results for the quarter ended September 30, 2026, including equity transactions such as ATM sales, private placements, and warrant exercises.
Key details
How SER stock reacted
Close before
$1.50
Nov 11, 2026
First close after
-6.00%
$1.41
5 trading days
—
Since filing
—
✦ Ask GOAX AI about this filing — what it means for SER, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for SER?
Click hereFrequently asked questions
What did SER file with the SEC on Nov 12, 2026?
SER filed a 10-Q (SEC filing). Serina Therapeutics filed its Q3 2026 Form 10-Q, reporting financial results for the quarter ended September 30, 2026, including equity transactions such as ATM sales, private placements, and warrant exercises.
How do I read a 10-Q?
The quarterly report: unaudited results for the quarter plus management’s comments. Compare revenue, margins and cash flow with the same quarter last year. Check MD&A for guidance changes and what drove the quarter.
Why are SEC filings important?
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 10-Q (quarterly report): The quarterly report: unaudited results for the quarter plus management’s comments.
How did SER stock react to this filing?
SER closed at $1.50 before the filing and $1.41 on Nov 12, 2026 (-6.00%).
Other SER SEC filings
Get alerts when SER files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days